Shire (SHPG) Upgraded to “Hold” by ValuEngine
ValuEngine upgraded shares of Shire (NASDAQ:SHPG) from a sell rating to a hold rating in a research note released on Friday.
Several other research analysts have also recently issued reports on SHPG. BidaskClub cut shares of Shire from a hold rating to a sell rating in a report on Thursday, August 16th. Kepler Capital Markets reissued a buy rating on shares of Shire in a report on Friday, May 11th. Cantor Fitzgerald set a $222.00 price target on shares of Shire and gave the stock a buy rating in a report on Tuesday, July 31st. Royal Bank of Canada reissued a buy rating on shares of Shire in a report on Tuesday, May 8th. Finally, BTIG Research reissued a buy rating and set a $195.00 price target on shares of Shire in a report on Sunday, April 29th. One analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the company. Shire has an average rating of Buy and an average target price of $201.18.
NASDAQ SHPG opened at $174.14 on Friday. The stock has a market cap of $52.23 billion, a P/E ratio of 11.06, a PEG ratio of 1.52 and a beta of 1.19. Shire has a 52-week low of $123.73 and a 52-week high of $177.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.55 and a quick ratio of 1.02.
Institutional investors have recently modified their holdings of the business. Rockefeller Capital Management L.P. purchased a new position in Shire in the first quarter valued at about $113,097,000. Mizuho Securities USA LLC purchased a new position in Shire in the second quarter valued at about $338,000. Creative Planning increased its holdings in Shire by 14.3% in the second quarter. Creative Planning now owns 6,555 shares of the biopharmaceutical company’s stock valued at $1,106,000 after buying an additional 818 shares in the last quarter. Hills Bank & Trust Co. purchased a new position in Shire in the second quarter valued at about $1,261,000. Finally, Pitcairn Co. increased its holdings in Shire by 280.3% in the first quarter. Pitcairn Co. now owns 7,054 shares of the biopharmaceutical company’s stock valued at $1,054,000 after buying an additional 5,199 shares in the last quarter. 17.82% of the stock is owned by institutional investors.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Read More: Price to Earnings Ratio (PE) Basics
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.